
	Where results make sense

Topic: Atosiban

Related Topics

Tocolytic

Nifedipine

Premature labour

Forceps

Application programming interface

Episiotomy

Saudi Arabia

	Atosiban
		Atosiban is better tolerated than β-agonists, however its short and long term safety for the mother and fetus is still unproved, thus we suggest its use should be considered only after failure of standard therapy of premature labor.
		Atosiban is a synthetic 9 amino acid peptide that corresponds to the oxytocin molecule modified in positions 1,2,4 and 8.
		The increase in perinatal mortality observed with atosiban may be due to the imbalance in the randomization of the extreme premature in the study that compares atosiban with a placebo and to the imbalance of the multiple pregnancies in the study that compares atosiban with ritodrine.
	www.ispub.com /ostia/index.php?xmlFilePath=journals/ijgo/vol2n1/atosiban.xml (3529 words)

	BioMed Central \| Full text \| The oxytocin/vasopressin receptor antagonist atosiban delays the gastric emptying of a ...
		(atosiban) (Ferring, Malmö, Sweden) is an antagonist to the oxytocin receptor.
		During infusion of the oxytocin receptor antagonist atosiban, the GER was significantly reduced by 37 % to 36 (22–48) % (Fig 1).
		In the obstetrics, where atosiban has been developed as a tocolytic drug, this is not a problem as an increased expression of oxytocin receptors but not vasopressin receptors is found in the uterus during labour [19].
	www.biomedcentral.com /1471-230X/6/11 (3263 words)

	Data Sheet
		In rats and guinea pigs, atosiban was shown to bind to oxytocin receptors, to decrease the frequency of contractions and the tone of the uterine musculature, resulting in a suppression of uterine contractions.
		Atosiban was also shown to bind to the vasopressin receptor, thus inhibiting the effect of vasopressin.
		It is unlikely that atosiban is involved in cytochrome P450 mediated medicine-medicine interactions as in vitro investigations have shown that atosiban is not a substrate for the cytochrome P450 system, and does not inhibit the medicine metabolising cytochrome P450 enzymes.
	www.medsafe.govt.nz /profs/Datasheet/t/Tractocileinj.htm (2349 words)

	OBLink Preterm Labor Resource - Congresses: Proceedings - COGI: ATOSIBAN: A Specific Evolution for the ...
		The concentration of atosiban in the maternal serum was twelve times that in the cord blood but there was obviously atosiban at therapeutic levels at the time of delivery.
		Atosiban is at least as effective as ß-agonists and with regard to maternal safety, there is a clear difference -the safety profile is very advantageous for atosiban.
		I believe we are all united in the view that preterm labour is not a single syndrome, but a whole group of different aetiologies in which tocolytic agents are suitable in certain cases but not all, and different combinations may be the answer in the future.
	oblink.com /display.asp?page=congresses_proceedings_COGI_atosiban_7&... (2194 words)

	OBLink Preterm Labor Resource - Clinical Practice Evaluation of atosiban in preterm labour management in six European ...
		The objectives of this study were three fold: firstly, to compare the efficacy of atosiban with usual care in the management of threatened preterm labour, secondly, to evaluate the efficacy and safety of early administration compared with standard administration of atosiban and thirdly, to describe treatment administration patterns of tocolytics in usual care.
		In the first part of the trial, women eligible to receive atosiban were randomised to receive atosiban or usual care (treatment with β-agonists, calcium channel blockers, magnesium sulphate, or any other tocolytic, alone or in combination, and/or bed rest).
		Atosiban was associated with fewer maternal and fetal adverse events and presented no safety concerns irrespective of the time it was administered.
	www.oblink.com /display.asp?page=abstracts_PTL2006_husslein (438 words)

	New drug for delaying premature birth marketed (Site not responding. Last check: 2007-10-15)
		Atosiban (Tractocile), an oxytocin antagonist for delaying premature birth, has been launched this week (see p892).
		Atosiban acts by preventing oxytocin from binding to its receptors in the uterus.
		Atosiban was given to 201 women with pre-term labour at 23-33 weeks gestation and a beta-agonist to 163 women.
	www.pharmj.com /editorial/20000610/clinical/prematurebirth.html (191 words)

	Tocolytics for preterm labour (Site not responding. Last check: 2007-10-15)
		When compared with placebo, atosiban resulted in lower birth weight (WMD -138.31 gm; 95% CI – 248.76 to -27,86), an increase in infant death at 12 months of age (RR 6.15;95% CI 1.39–27.22) and an increase in maternal adverse drug reaction (RR 4.02; 95%CI 2.05 to 7.85).
		Atosiban was associated with significantly less maternal drug reactions when compared with betamimetics (RR 0.04; 95% CI 0.02–0.11).
		Moreover, atosiban did not reduce the incidence of delivery before 48 hours after initiation of treatment, respiratory distress syndrome and admission to neonatal intensive care.
	www.rhlibrary.com /Commentaries/htm/Socom.htm (633 words)

	atosiban (Site not responding. Last check: 2007-10-15)
		Agrees, i promise to marry or atosiban atosiban attributes that atosiban.
		Teilnehmer wolfgang clement, or atosiban halb philosophie-kolloqium, halb politikum, fand moderator.
		Are atosiban auf alle mitglieder der spezies vollstandigen individuums rechtssprechung beginnt.
	atosiban.4speed.org (1617 words)

	Oxytocin receptor antagonists for inhibiting preterm labour (Cochrane Review)
		This review found that, although the oxytocin receptor antagonist atosiban resulted in fewer maternal side-effects than other tocolytic drugs (betamimetics), no benefit was shown in delaying or preventing preterm birth, and atosiban was associated with more infant deaths in one placebo controlled trial.
		In one trial (583 infants), atosiban was associated with an increase in infant deaths at 12 months of age compared with placebo (relative risk (RR) 6.15; 95% confidence intervals (CI) 1.39 to 27.22).
		Atosiban was associated with fewer maternal drug reactions requiring treatment cessation (RR 0.04; 95% CI 0.02 to 0.11, number needed to treat 6; 95% CI 5 to 7, 4 trials, 1035 women).
	www.update-software.com /Abstracts/AB004452.htm (619 words)

	Tractocile 7.5 mg/ml Solution for Injection , SPC from the eMC
		Possible undesirable effects of atosiban were described for the mother during the use of atosiban in clinical trials.
		As the safety and efficacy of atosiban in women with a gestational age of less than 24 completed weeks has not been established in controlled randomised studies, the treatment of this patient group with atosiban is not recommended (see section 4.3).
		Eleven out of the 15 deaths in the atosiban group occurred in pregnancies with a gestational age of 20 to 24 weeks, although in this subgroup patient distribution was unequal (19 women on atosiban, 4 on placebo).
	emc.medicines.org.uk /emc/assets/c/html/displaydoc.asp?documentid=4297 (2109 words)

	Tractocile 7.5 mg/ml Concentrate for Solution for Infusion , SPC from the eMC
		When atosiban is used in patients in whom premature rupture of membranes cannot be excluded, the benefits of delaying delivery should be balanced against the potential risk of chorioamnionitis.
		There is only limited clinical experience in the use of atosiban in multiple pregnancies or the gestational age group between 24 and 27 weeks, because of the small number of patients treated.
		It is unlikely that atosiban is involved in cytochrome P450 mediated drug-drug interactions as in vitro investigations have shown that atosiban is not a substrate for the cytochrome P450 system, and does not inhibit the drug metabolising cytochrome P450 enzymes.
	emc.medicines.org.uk /emc/assets/c/html/displaydoc.asp?documentid=4305 (2342 words)

	[No title]
		That‘ s why not only all of the single branch atosiban published studies were used, but also an effort became the atosiban branch trials to be mined by controlled ones, without interest in what the control groups get.
		The atosiban branch of 252 women continued this medication as maintenance treatment, while the other control branch women were given placebo, until 36weeks.
		Detailed numeric data and a side effects and neonatal mortality profile of this atosiban branch trial are depicted in tables 1-6. The eighth study was performed by Moutquin et al.
	www.dadlnet.dk /dmb/dmb_phd/doc/manuscript.doc (1945 words)

	Human Atosiban - HOR-239
		Atosiban has a specific mode of action, inhibiting oxytocin-induced uterine contractions lry blocking oxytocin receptors in the uterus.
		Extensive clinical investigations have shown Atosiban to be at least as effective as current tocolytic agents.
		It is recommended to reconstitute the lyophilized Atosiban in sterile 18MΩ-cm H
	www.prospec.co.il /~prospec/cart/catalog/Atosiban.html (270 words)

	The Oxytocin Receptor Antagonist Atosiban Inhibits Cell Growth via a "Biased Agonist" Mechanism -- Reversi et al. 280 ...
		Atosiban and OT-induced effects on proliferation in MCDK and HEK293 cells stably expressing the human OTR.
		atosiban induced a persistent increase in ERK1/2 phosphorylation,
		to OT and atosiban for 48 h (Fig.
	www.jbc.org /cgi/content/full/280/16/16311 (5084 words)

	Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Atosiban Study Group -- ...
		OBJECTIVE: To evaluate the minimal effective dose regimen of the oxytocin antagonist atosiban in the treatment of acute preterm labor and the effect of a bolus on uterine activity within the first 2 hours compared with no bolus and the same infusion rate.
		Bolus therapy with high-dose atosiban resulted in a significantly greater proportion of patients who stopped contracting within the first 2 hours of treatment (17 of 63) compared with those not receiving a bolus (six of 58, P =.017).
		CONCLUSION: Atosiban's effect on uterine activity in preterm labor was enhanced by bolus infusion and was similar to the effect of ritodrine, but with fewer side effects.
	www.greenjournal.org /cgi/content/abstract/88/3/331 (332 words)

	Medscape MEDLINE search: Ritodrine
		The in vitro effect of dual combinations of ritodrine, nicardipine and atosiban on contractility of pregnant rat myometrium.
		Atosiban vs ritodrine used prophylactically with cerclage in ICSI pregnancies to prevent pre-term birth in women identified as being at high risk on the basis of transvaginal ultrasound scan.
		Multicentre, parallel group, randomised, single-blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women.
	search.medscape.com /uslclient/searchMedline.do?queryText=Ritodrine (1199 words)

	上海市计划生育技术指导所 (Site not responding. Last check: 2007-10-15)
		Barusiban has greater potency and longer duration of action than atosiban (Tractocile), a combined vasopressin and oxytocin receptor antagonist recently approved in Europe for preterm labor, the researchers note in the April issue of the Journal of Clinical Endocrinology and Metabolism.
		He and his colleagues compared the tocolytic effects of an IV bolus of barusiban with that of atosiban in pregnant cynomolgus monkeys with oxytocin-stimulated contractions.
		Barusiban, however, was significantly more potent than atosiban, producing the same level of intrauterine pressure inhibition at roughly 4-fold lower blood levels due to its higher affinity and selectivity for the oxytocin receptor.
	www.shrhfp.org.cn /200503/jsp/info_show.jsp?sys_id=med2005_05_23_30271 (368 words)

	OBLink Preterm Labor Resource - Congresses: Proceedings - COGI: ATOSIBAN: A Specific Evolution for the ...
		Atosiban was given for up to 48 hours by i.v.
		atosiban is associated with a significantly higher proportion of women remaining undelivered and not requiring alternative tocolysis up to 7 days of starting treatment.
		treatment with atosiban, subcutaneous maintenance therapy was also associated with prolonging the time interval to first recurrence of labour and reducing the need for subsequent i.v.
	www.oblink.com /display.asp?page=congresses_proceedings_COGI_atosiban_4&subsec=atosiban (647 words)

	department of chemistry (Site not responding. Last check: 2007-10-15)
		Atosiban 2, an oxytocin antagonist, is used for prevention of preterm labor and premature birth.
		The half-lives of peptides 8 and 18 in rat placental tissue were shown to be greatly improved versus their parents oxytocin 1 and atosiban 2, respectively.
		These results suggest that peptides 8 and 18 and analogues thereof may be important leads into the development of a long-lasting, commercially available therapeutic for initiation of parturition and treatment of preterm labor.
	www.chem.ualberta.ca /about/highlights/jcv_september2005.html (268 words)

	Oxytocin antagonists : atosiban ( Tractocile )
		Atosiban, an oxytocin receptor antagonist, is effective in the treatment of an acute episode of preterm labor.
		This study was designed to compare the efficacy and safety of atosiban with those of placebo maintenance therapy in women with preterm labor who achieved uterine quiescence with intravenous atosiban.Study Design: A multicenter, double-blind, placebo-controlled trial was designed for patients in preterm labor who responded to early intravenous treatment with atosiban.
		At least one subsequent intravenous atosiban treatment was needed by 61 atosiban patients (23%) and 77 placebo patients (31%).
	oxytocin.org /oxy/antagonist.html (361 words)

	World Experts Gather To Reduce Burden Of Premature Birth (Site not responding. Last check: 2007-10-15)
		The study set out to compare the efficacy of Tractocile with usual care (b-agonists, alone or with magnesium, calcium channel blockers and bed rest) in threatened preterm labour, to evaluate the efficacy and safety of early administration of Tractocile and to describe treatment administration patterns of tocolytics in usual care.
		“Atosiban was statistically more efficacious than usual care when assessed using our primary efficacy endpoint of the proportion of women remaining undelivered and not requiring an alternative tocolytic at 48 hours”, points out Professor Husslein.
		Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour.
	www.pharma-lexicon.com /medicalnews.php?newsid=42495 (696 words)

	Oxytocin antagonists: clinical and scientific considerations -- Thornton et al. 86 (2): 297 -- Experimental Physiology
		The reasons are numerous and complex, but they include a failure to understand the mechanism(s) of preterm labour, the multitude of different causes, the difficulty in diagnosis and the problems of outcome measurement in clinical trials.
		Atosiban has an effect at both oxytocin and vasopressin (V(1a)) receptors, which (assuming efficacy) raises the question as to whether oxytocin or vasopressin V(1a) antagonism is required for tocolysis.
		This review examines the rationale for tocolysis in preterm labour, the evidence for administration of atosiban and the role for oxytocin, vasopressin and their receptors in the onset of labour.
	ep.physoc.org /cgi/content/abstract/86/2/297 (380 words)

	Effects of Oxytocin Receptor Antagonist Atosiban on Pregnant Myometrium In Vitro -- Büscher et al. 98 (1): 117 -- ... (Site not responding. Last check: 2007-10-15)
		Effects of Oxytocin Receptor Antagonist Atosiban on Pregnant Myometrium In Vitro -- Büscher et al.
		Atosiban was supplied by the FERRING AB, Copenhagen, Denmark.
		The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human.
	www.greenjournal.org /cgi/content/full/98/1/117 (1839 words)

	Barusiban, A New Highly Potent and Long-Acting Oxytocin Antagonist: Pharmacokinetic and Pharmacodynamic Comparison with ...
		Atosiban (TRACTOCILE) is a combined vasopressin (V1a) and OT receptor antagonist and the first tocolytic developed and approved
		The duration of action was approximately 8 h for barusiban, compared with 1 h for atosiban.
		with atosiban, and clearance was decreased approximately 8-
	jcem.endojournals.org /cgi/content/full/90/4/2275 (4101 words)

	Effect of Oxytocin Receptor and ß2-Adrenoceptor Blockade on Myometrial Oxytocin Receptors in Parturient Rats -- ...
		Membranes were isolated from untreated rats at different gestational ages and from rats in labor treated with saline, atosiban (5 µg/h), ICI-118.551 (1.5 mg twice daily), or both atosiban and ICI-118.551 (same doses as individual treatments) from Day 18 of pregnancy.
		Strips were isolated from rats in labor treated with saline (circles), atosiban (open squares, 5 µg/h), ICI-118.551 (stars, 1.5 mg twice daily), or both atosiban and ICI-118.551 (solid squares, same doses as individual treatments) from Day 18 of pregnancy.
		Maternal and fetal cardiovascular effects and placental transfer of the oxytocin antagonist atosiban in late-gestation pregnant sheep.
	www.biolreprod.org /cgi/content/full/60/2/322 (5067 words)

	Atosiban ( Tractocile ) (Site not responding. Last check: 2007-10-15)
		Women (n=241) diagnosed with preterm labor at 23-33 gestational weeks were enrolled and received either atosiban (n=119) or salbutamol (n=122).
		CONCLUSIONS: The oxytocin antagonist atosiban was found to be better tolerated by both mother and fetus than salbutamol, with a comparable neonatal and infant safety profile, and atosiban was as effective as salbutamol in delaying threatened preterm birth.
		This study supports the clinical use of atosiban in the treatment of preterm labor.
	oxytocin.org /oxy/atosiban.html (313 words)

Try your search on: Qwika (all wikis)